Mon Sep 16 15:15:36 UTC 2024: ## Biotech Stocks Heating Up: Exicure, Syros, BioNTech, Arcturus, and Vaxart See Increased Investor Interest

**[City, State] – [Date]** – Several biotech companies are seeing a surge in investor interest, according to data from InvestingChannel, a leading online financial news platform. These companies include Exicure, Syros, BioNTech, Arcturus Therapeutics, and Vaxart.

**Exicure** is developing nucleic acid therapies targeting RNA for various diseases. They are actively seeking out-licensing opportunities for their clinical asset, cavrotolimod, and preclinical candidates, including the SCN9A program for neuropathic pain.

**Syros** focuses on developing treatments for hematologic malignancies, with tamibarotene, an oral selective RARalpha agonist, being developed for higher-risk myelodysplastic syndrome and acute myeloid leukemia.

**BioNTech**, known for its mRNA COVID-19 vaccine, is pioneering novel therapies for cancer and other diseases. They are developing multiple mRNA vaccine candidates and have partnerships with several pharmaceutical giants, including Pfizer, Sanofi, and Regeneron.

**Arcturus Therapeutics**, a late-stage clinical mRNA medicines and vaccines company, has a pipeline of RNA therapeutic and vaccine candidates for various diseases including COVID-19, influenza, and cystic fibrosis. Their updated self-amplifying mRNA COVID-19 vaccine, Kostaive, has received approval in Japan.

**Vaxart** is developing oral recombinant vaccines based on its proprietary delivery platform. They are aiming to develop oral versions of existing vaccines and design new vaccines for various diseases, including norovirus, coronavirus, influenza, and HPV.

**JPMorgan** recently upgraded BioNTech to Neutral from Underweight, citing promising Phase II and Phase I/II data for BNT327/PM8002, a bispecific antibody, and highlighting the company’s diversification beyond COVID-19.

This surge in interest could be driven by upcoming clinical study results, FDA approvals, or other major events that can significantly impact stock prices in the volatile biotech sector.

**Investors** are advised to conduct their own due diligence before investing in any biotech company.

Read More